MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
5.69
+0.57
+11.13%
Pre Market: 5.79 +0.1 +1.76% 05:14 01/08 EST
OPEN
5.32
PREV CLOSE
5.12
HIGH
5.87
LOW
5.25
VOLUME
26
TURNOVER
0
52 WEEK HIGH
7.82
52 WEEK LOW
2.770
MARKET CAP
293.78M
P/E (TTM)
-3.9868
1D
5D
1M
3M
1Y
5Y
1D
3 Best Biotech Stocks to Buy Today, 1/7/2026, According to Top Analysts
TipRanks · 21h ago
Protara Therapeutics Price Target Announced at $24.00/Share by Piper Sandler
Dow Jones · 22h ago
Protara doses first patient in Phase 3 trial of IV Choline Chloride
TipRanks · 22h ago
Protara Therapeutics Announces Patient Dosing In Phase 3 Registrational THRIVE-3 Clinical Trial Evaluating IV Choline Chloride In Patients Receiving Long-Term Parenteral Support
Benzinga · 22h ago
Protara Therapeutics Begins Phase 3 Trial of IV Choline Chloride in Long-Term Parenteral Support Patients
Reuters · 22h ago
PROTARA THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 REGISTRATIONAL THRIVE-3 TRIAL OF IV CHOLINE CHLORIDE IN PATIENTS ON LONG-TERM PARENTERAL SUPPORT
Reuters · 22h ago
Protara Therapeutics initiated with an Overweight at Piper Sandler
TipRanks · 1d ago
U.S. RESEARCH ROUNDUP-Alphabet, Hershey, Micron Technology
Reuters · 1d ago
More
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Webull offers Protara Therapeutics Inc stock information, including NASDAQ: TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.